Industry Experts

Dr. Liu is an experienced biotechnologist, virologist, biochemist and serial entrepreneur. Prior to Avirmax, Dr. Liu held an executive position, chief scientist and global head of Pathogen Safety of Bayer Pharmaceuticals for 15 years. Dr. Liu was a founder and the president of Abmaxis, Inc. which was acquired by Merck in 2006. Dr. Liu was the group leader of Genentech BSL-3 Virology Research Lab (1996-2000). In his scientific career, he developed bioprocess technologies to prevent commercial scale bioreactors from virus contamination and secured virus safety for biotherapeutics. He discovered and characterized a new virus, rabbit hemorrhagic disease virus (RHDV), the rabbit calicivirus in 1984. During his past 25 years of biotechnological career, he played key roles in innovation, development, tech transfer and manufacturing support and regulatory submission for approvals at various development stages of 33 biologics including AAV mediated GT products, out of which 10 are widely used biologics in the market. Now he is focusing primarily on AAV & GOI engineering, innovation, development and production for ocular disorders. Dr. Liu received his Ph.D. from Biochemistry from Kansas State University (1990-93) and his post-doctoral training with Dr. Arthur Kornberg, Stanford University (1994-1996). Dr. Liu is a member of ASGCT, ARVO and an advisor of Bioengineering Department of Santa Clara University (Santa Clara, CA).